



22 April 2021  
EMA/CHMP/802679/2018 Rev.1\* Corr. 1\*\*  
Committee for Medicinal Products for Human Use (CHMP)

## Palbociclib hard capsule 75 mg, 100 mg and 125 mg and film-coated tablet 75 mg, 100 mg and 125 mg product-specific bioequivalence guidance

<b>Draft Agreed by Pharmacokinetics Working Party (PKWP)</b>	October 2018
<b>Adopted by CHMP for release for consultation</b>	31 January 2019
<b>Start of public consultation</b>	8 February 2019
<b>End of consultation (deadline for comments)</b>	30 June 2019
<b>Draft Agreed by Pharmacokinetics Working Party (PKWP)</b>	September 2019
<b>Adopted by CHMP</b>	19 September 2019
<b>Date of coming into effect</b>	1 April 2020
<b>Draft revision agreed by Pharmacokinetics Working Party</b>	October 2020
<b>Adopted by CHMP for release for consultation</b>	12 November 2020
<b>Start of public consultation</b>	23 November 2020
<b>End of consultation (deadline for comments)</b>	28 February 2021
<b>Agreed by Pharmacokinetics Working Party</b>	11 March 2021
<b>Adopted by CHMP</b>	22 April 2021
<b>Date of coming into effect</b>	1 April 2022

**Official address** Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

**Address for visits and deliveries** Refer to [www.ema.europa.eu/how-to-find-us](http://www.ema.europa.eu/how-to-find-us)

**Send us a question** Go to [www.ema.europa.eu/contact](http://www.ema.europa.eu/contact) **Telephone** +31 (0)88 781 6000

An agency of the European Union



\*This revision concerns the addition of requirements for a tablet.

\*\* The date of coming into effect has been extended due to a delay in publication.

<b>Keywords</b>	<b><i>Bioequivalence, generics, palbociclib</i></b>
-----------------	---

## Palbociclib hard capsule 75 mg, 100 mg and 125 mg and film-coated tablet 75 mg, 100 mg and 125 mg product-specific bioequivalence guidance

### **Disclaimer:**

***This guidance should not be understood as being legally enforceable and is without prejudice to the need to ensure that the data submitted in support of a marketing authorisation application complies with the appropriate scientific, regulatory and legal requirements.***

Requirements for bioequivalence demonstration (PKWP)\*

<b>BCS Classification**</b>	<b>BCS Class:</b> <input type="checkbox"/> I <input type="checkbox"/> III <input checked="" type="checkbox"/> <b>Neither of the two</b> <b>Background:</b> Palbociclib is considered a low solubility compound.
<b>Bioequivalence study design</b> <i>in case a BCS biowaiver is not feasible or applied</i>	<b>single dose</b> <b>cross-over</b>
	<b>healthy volunteers</b>
	Capsules: <input type="checkbox"/> <b>fasting</b> <input checked="" type="checkbox"/> <b>fed</b> <input type="checkbox"/> <b>both</b> <input type="checkbox"/> <b>either fasting or fed</b> Tablets:

	<input checked="" type="checkbox"/> <b>fasting</b> <input type="checkbox"/> <b>fed</b> <input type="checkbox"/> <b>both</b> <input type="checkbox"/> <b>either fasting or fed</b> <p>In addition to the regular study under fasting conditions a fasting study under conditions of multiple day pre-treatment with a proton pump inhibitor (PPI), such as pantoprazole (40 mg b.i.d. for 4 days), should be conducted.</p> <p><b>Background:</b> Solubility of palbociclib is pH dependent. PPIs may affect the bioavailability of palbociclib under fasting conditions differently depending on the formulation.</p> <hr/> <p><b>Strength:</b> 125 mg</p> <p><b>Background:</b> Highest strength for drugs with linear pharmacokinetics and low solubility.</p> <hr/> <p><b>Number of studies:</b></p> <p>Capsules: One single-dose study (fed state)</p> <p>Tablets: Two single-dose studies (fasting and under conditions of pre-treatment with a PPI).</p>
<b>Analyte</b>	<input checked="" type="checkbox"/> <b>parent</b> <input type="checkbox"/> <b>metabolite</b> <input type="checkbox"/> <b>both</b> <input checked="" type="checkbox"/> <b>plasma/serum</b> <input type="checkbox"/> <b>blood</b> <input type="checkbox"/> <b>urine</b> <b>Enantioselective analytical method:</b> <input type="checkbox"/> <b>yes</b> <input checked="" type="checkbox"/> <b>no</b>
<b>Bioequivalence assessment</b>	<p><b>Main pharmacokinetic variables:</b> AUC<sub>0-72h</sub>, C<sub>max</sub></p> <hr/> <p><b>90% confidence interval:</b> 80.00 – 125.00%</p>

\* As intra-subject variability of the reference product has not been reviewed to elaborate this product-specific bioequivalence guideline, it is not possible to recommend at this stage the use of a replicate design to demonstrate high intra-subject variability and widen the acceptance range of C<sub>max</sub>. If high intra-individual variability (CV<sub>intra</sub> > 30%) is expected, the applicants might follow respective guideline recommendations.

\*\* This tentative BCS classification of the drug substance serves to define whether *in vivo* studies seems to be mandatory (BCS class II and IV) or, on the contrary (BCS Class I and III), the Applicant may choose between two options: *in vivo* approach or *in vitro* approach based on a BCS biowaiver. In this latter case, the BCS classification of the drug substance should be confirmed by the Applicant at the time of submission based on available data (solubility experiments, literature, etc.). However, a BCS-based biowaiver might not be feasible due to product specific characteristics despite the drug substance being BCS class I or III (e.g. *in vitro* dissolution being less than 85% within 15 min (BCS class III) or 30 min (BCS class I) either for test or reference, or unacceptable differences in the excipient composition).